AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for MORC family CW-type zinc finger protein 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8TE76

UPID:

MORC4_HUMAN

Alternative names:

Zinc finger CW-type coiled-coil domain protein 2; Zinc finger CW-type domain protein 4

Alternative UPACC:

Q8TE76; A1YR23; A1YR24; H7BXF1; Q5JUK7; Q96MZ2; Q9HAI7

Background:

The MORC family CW-type zinc finger protein 4, also known as Zinc finger CW-type coiled-coil domain protein 2 and Zinc finger CW-type domain protein 4, plays a crucial role in histone methylation. It specifically binds to various methylated states of 'Lys-4' on histone H3, with a preference order of H3K4me3 > H3K4me2 > H3K4me1 > H3K4me0. This binding ability underscores its significance in epigenetic regulation.

Therapeutic significance:

Understanding the role of MORC family CW-type zinc finger protein 4 could open doors to potential therapeutic strategies. Its involvement in histone methylation positions it as a key player in epigenetic mechanisms, which are crucial for gene expression regulation and have implications in numerous diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.